RxDoctor Payments Data

Abdulla Abdulla, MD

Cardiovascular Disease · Augusta, GANPI 1174502694

Payments from drug & device makers

$902in general payments, 2019–2025

Across 37 payments — averaging $24.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$179
  • Boston Scientific$148
  • Astellas Pharma US Inc$100
  • Philips North America LLC$84
  • Pfizer$83
  • Abiomed$79
  • plus $230 from 7 others

What the payments were for

  • Food & beverage$80289%
  • Education$10011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$902 in reported general payments places this provider in the 30th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$156,963
Medicare patients
1,476
Services billed
2,801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban693$627,215
EntrestoSacubitril/Valsartan232$210,719
JardianceEmpagliflozin58$66,592
XareltoRivaroxaban44$53,342
Repatha SureclickEvolocumab54$35,390
FarxigaDapagliflozin Propanediol31$26,415
Praluent PenAlirocumab11$11,665
Metoprolol Succinate758$10,895
BrilintaTicagrelor14$9,593
Flecainide Acetate71$5,104
ClopidogrelClopidogrel Bisulfate376$4,304
Nitroglycerin94$4,102
Losartan Potassium402$3,693
Isosorbide Dinitrate37$3,526
Atorvastatin Calcium336$3,313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$83$627,215693 claims
NovartisEntresto$24$210,719232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →